Navigation Links
Orexigen Resubmits Contrave New Drug Application
Date:12/11/2013

risk profile for Contrave; and the execution of the Contrave U.S. launch by Takeda; Orexigen's plans to seek a commercialization partner in territories outside of North America; and the timing of the submission of the CSR for the interim analysis. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the CSR for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave even after meeting the prespecified threshold and resubmitting the NDA; the possibility that public disclosure of the results of the interim analysis would later be deemed to jeopardize the integrity of the Light Study potentially resulting in the requirement to conduct additional, costly studies; additional analysis of the interim results or new data from the continuing Light Study, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with the conclusion that the interim analysis was successful; the potential that the interim analysis may not be predictive of future results in the Light Study; the potential for early termination of Orexigen's North American collaboration agreement with Takeda; the results from the interim analysis may not be sufficient to satisfy or respond to the Day 120 List of Questions from the EMA or any other data requirements of the EMA in conn
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
5. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
6. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
7. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
8. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... According to a new market research report ... Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), ... MarketsandMarkets, the Medical Lifting Sling Market is poised to reach USD ... a CAGR of 11.4 % from 2015 to 2020. ... data T ables and 65 F ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: ... announced that positive results from its Phase 1 ... patients with moderate hepatic impairment, will be presented ... and Therapeutics (ASCPT) 112th Annual Meeting in Dallas, ...
Cached Medicine Technology:Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 2Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting 3
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Test To Provide Physicians in U.S. and Europe ... , MADISON, N.J., June 2 HemoCue AB, an ... subsidiary of Quest Diagnostics Incorporated (NYSE: DGX ), ... Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) ...
... NEW YORK, June 2 , ... FOI Documents Through 1991 , ... clinical and post-marketing drug,information, has significantly expanded its coverage ... the launch of the FDA Classic,Collection. This collection contains ...
... June 2 Versus Technology, Inc. (Pink Sheets: VSTI) ... and OR Solutions to Chalmers P. Wylie Veterans Ambulatory ... rules-based real-time location information system (RTLiS) will be installed ... surgery center and clinics. , , The ...
... , , , Approval for ... Pa., June 2 B. Braun Medical Inc. (B. Braun), a ... U.S. Food and Drug Administration (FDA) approval for 2g ... DUPLEX(R) Drug Delivery System . , , (Logo: ...
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that could influence the way researchers screen for, treat ... cancer, an aggressive form of the disease. One finding ... "Women with locally advanced breast cancer and their ... mass should not be ignored even if someone has ...
Cached Medicine News:Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 2Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 3Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 2Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 3Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 2Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 3Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 3
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Freer elevator, double end, 7 1/4", S/B....
Stainless steel dull finish....
The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
Medicine Products: